Terazosin hydrochloride
USP/1643452 - United States Pharmacopeia (USP) Reference Standard
Synonym: Terazosin hydrochloride dihydrate; 1-
CAS Number: 70024-40-7
Empirical Formula (Hill Notation): C19H25N5O4 · HCl · 2H2O
Molecular Weight: 459.92
MDL Number: MFCD00941408
Linear Formula: C19H25N5O4 · HCl · 2H2O
Product Type: Chemical
| API family | terazosin |
| application(s) | pharmaceutical (small molecule) |
| format | neat |
| grade | pharmaceutical primary standard |
| InChI | 1S/C19H25N5O4.ClH.2H2O/c1 |
| InChI key | NZMOFYDMGFQZLS-UHFFFAOYSA |
| manufacturer/tradename | USP |
| SMILES string | O.O.Cl.COc1cc2nc(nc(N)c2c |
| Analysis Note: | These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind. |
| Application: | Terazosin hydrochloride USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as: • Terazosin Capsules • Terazosin Tablets |
| General description: | Terazosin hydrochloride is a quinazoline derivative. It is a alpha-1-selective adrenoceptor blocking agent. It has been used to treat hypertension, as it helps the blood vessels to relax, expand and improves blood flow. |
| Other Notes: | Sales restrictions may apply. |
| Symbol | GHS07 |
| Signal word | Warning |
| Hazard statements | H302 |
| Precautionary statements | P301 + P312 + P330 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| UNSPSC | 41116107 |

